-
A second human papillomavirus (HPV) recombi-nant vaccine has been approved by the FDA.
-
The HOPE trial convinced many experts that midlife adults (age ≥ 55 years) with existing vasculopathy (history of CAD, CVD, diabetes and CV risk factors) will have improved outcomes on an ACE inhibitor (ramipril, to be specific).
-
Advanced dementia mortality rates rise after episodes of fever, pneumonia, and eating problems. Treatment decisions often lead to burdensome interventions and distressing symptoms that might be avoided if caregivers were better informed about the expected complications and prognosis of this condition.
-
The emerging risk factors colla-boration collected data from prospective observational studies of persons without CV disease at baseline (n = 69 studies, with 302,430 participants). Lipid fractions measured in these studies included LDL, HDL, apo B, and apo A1. Risk for incurring CV endpoints was stratified for each lipid fraction.
-
A significant proportion of patients with difficult- to-control asthma are non-adherent to both inhaled and oral corticosteroid therapy.
-
Data early on in the pandemic influenza outbreak suggested that most severely ill patients with influenza A were not suffering from bacterial co-infection.
-
A monoclonal antibody against interleukin-12 and interleukin-23 has been approved by the FDA for the treatment of plaque psoriasis. Ustekinumab is marketed as a subcutaneous injection by Centocor Ortho Biotech as Stelara™.
-
The ECG shown above was obtained from a 60-year-old man with a history of a dilated cardiomyopathy. Given this information, what clinical concerns might you have if this patient presented to the emergency department in heart failure with the tracing above?
-
Congestive heart failure (CHF) is the most common DRG for Medicare patients in U.S. hospitals and is therefore the target of considerable regulatory attention due to its financial impact on the federal budget.
-
Results from a Phase 3 study of dabigatran, intensive lipid-lowering in CVD, H1N1 vaccine dosing and efficacy, and FDA Actions
